Promomed Group's net profit under IFRS for 2025 increased 2.5 times to 7.168 billion rubles from 2.87 billion rubles a year earlier. This is evidenced by the company's data.
EBITDA increased by 86% to 15.3 billion rubles from 8.2 billion rubles, revenue increased by 75.2% to 37.57 billion rubles from 21.45 billion rubles.
The Group's strategic areas of endocrinology and oncology accounted for 76% of revenue. Thus, the revenue of the segment "Endocrinology" increased by 163% and reached 21.6 billion rubles, "Oncology" - by 42% to 7 billion rubles.
Export sales revenue amounted to 0.9 billion rubles, an increase of 65%.
The number of employees as of December 31, 2025 increased by 28% to 2,826 thousand.
The total remuneration to the group's key management personnel represents short-term payments and liabilities, as well as expenses under the long-term incentive program, and is included in general and administrative expenses in the consolidated statement of profit or loss and other comprehensive income for the year ended December 31, 2025 in the amount of RUB 901,958 million. (for the year ended December 31, 2024 – RUB 308.225 million).
The total number of key management personnel of the group as of December 31, 2025 was 6 people (as of December 31, 2024 – 7 people).
In September 2025, the reorganization of PROMOMED RUS LLC was completed in the form of NPC Antibiotics LLC joining it due to the termination of the latter's activities.
On March 15, 2024, the Group completed the acquisition of a 77.94% stake in Promomed Holdings LLC. At the time of the acquisition, Promomed Holdings LLC owned 100% of the shares of Promomed Holdings (Cyprus) Limited. The purpose of the transaction is to buy out 6% of shares of PJSC PROMOMED owned by Promomed Holdings (Cyprus) Limited. The value of the transaction amounted to RUB 928.25 million on March 28, 2025, the group fully repaid the outstanding debt under the transaction.
In March 2026, the company's board of directors decided to exclude from the dividend policy the requirement for a positive operating cash flow as a prerequisite for the payment of dividends. The change will allow the company to consider the economic validity of payments in the broader context of financial results while maintaining a balanced approach to capital allocation between investments in growth and creating shareholder value, the report says.
During 2025 and 2024, the group did not declare or pay dividends. In 2025, the group made other capital distributions in favor of the owners in the amount of 473.243 million rubles, taking into account the restoration of the previously recognized estimated liability. In 2024, the group made other capital distributions in favor of the owners in the amount of RUB 13.753 million.
Promomed Group was initially established by several individuals as a group of companies operating in the pharmaceutical market of the Russian Federation.
PJSC Promomed (the parent company of the group) was established on July 16, 2021.
As of December 31, 2025, Peter Bely was the ultimate controlling owner of the group. As of December 31, 2024, he owns 87.67% of the authorized capital, and 82.5% as of December 31, 2025. As of December 31, 2024, a 5.65% stake belonged to Promomed Holdings LLC, with 6.68% held nominally. In 2025, Promomed Holdings LLC transferred its stake to UK ARTES LLC (the management company of ZPIF Smaragd).
As of December 31, 2025, the shareholders are: Peter Bely – 87.67%, other shareholders – 12.33%.
Non-controlling interests as at December 31, 2025: 10% in the authorized capital of Promark LLC, 50.44% (as of December 31, 2024, 49%) in the authorized capital of Berakhim LLC; 22.06% in the authorized capital of Promomed Holdings LLC; 31.98% (as of December 31, 2024, 30%) in the authorized capital of Promomed – Animal Health LLC"; 2.83% in the authorized capital of Miracle Farm LLC; 2.83% in the share capital of Biochemist JSC; 21.92% in the property of ZPIF Smaragd.
The net profit of PJSC Promomed under RAS for 2025 amounted to 123.45 million rubles against a loss of 69.375 million rubles a year earlier.
Promomed increased its net profit under IFRS for the first half of 2025 by 283 times to 1.418 billion rubles from 5 million rubles a year earlier. Revenue increased by 82% to 12.97 billion rubles from 7.13 billion rubles, gross profit – by 91.6% to 7.968 billion rubles from 4.16 billion rubles, EBITDA – by 91% to 4.368 billion rubles from 2.285 billion rubles.
